Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) Genotypes.

ABSTRACT:

Background

The role of aspirin in reducing lipoprotein(a)-mediated atherothrombotic events in primary prevention is not established.

Objectives

This study sought to assess whether low-dose aspirin benefits individuals with elevated plasma lipoprotein(a)-associated genotypes in the setting of primary prevention.

Methods

The study analyzed 12,815 genotyped individuals ≥70 years of age of European ancestry and without prior cardiovascular disease events enrolled in the ASPREE (ASPirin in Reducing Events in the Elderly) randomized controlled trial of 100 mg/d aspirin. We defined lipoprotein(a)-associated genotypes using rs3798220-C carrier status and quintiles of a lipoprotein(a) genomic risk score (LPA-GRS). We tested for interaction between genotypes and aspirin allocat

SUBMITTER: Lacaze P 

PROVIDER: S-EPMC10025998 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature